• Prescience Labs LLC, of Potomac, Md., said the FDA has approved its investigational new drug application for Phase I clinical evaluation of its anti-cancer drug 3-bromopyruvate (PSL-001) in patients with primary and/or metastatic liver cancer. The study will evaluate the dosing regimen of the drug to determine the maximum tolerated dose based on the safety data.